{"filings":[{"id":2051923,"accession_number":"0001193125-26-332858","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-08-04T20:16:35+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q2 revenue up 16% to $308M; raises FY2026 guidance to $1.24-1.30B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["DAYBUE net sales $125M (+30% YoY); NUPLAZID net sales $183M (+10% adj. YoY).","Full-year 2026 total revenue guidance raised to $1.24-1.30B; DAYBUE guidance raised to $480-510M.","Phase 2 remlifanserin topline results for Alzheimer's disease psychosis expected Sept-Oct 2026.","CHMP positive opinion for DAYBUE in EU for Rett syndrome; FDA Fast Track for remlifanserin.","CEO reaffirms long-term ambition of ~$1.7B annual net sales by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":746530,"accession_number":"0001193125-26-248242","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-05-29T20:05:14+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Acadia shareholders approve 5.2M-share increase to 2024 equity plan, re-elect three Class I directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 5,209,670.","Re-elected Class I directors James M. Daly, Edmund P. Harrigan, and Adora Ndu to Board until 2029.","Advisory vote on executive compensation approved with 98.7% of votes cast in favor.","Ernst & Young ratified as independent auditor for FY2026 with 157,409,378 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91085,"accession_number":"0001193125-26-209253","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q1 revenue $268M (+10% YoY); DAYBUE sales $101M (+20%); reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total Q1 revenues $268M (+10% GAAP YoY, +11% adj); NUPLAZID $167M (+5% GAAP, +6% adj); DAYBUE $101M (+20%).","DAYBUE STIX launch underway; ~30% of STIX patients treatment-naive or returning after liquid discontinuation.","Phase 2 remlifanserin topline data in Alzheimer's disease psychosis expected Aug–Oct 2026, on track.","Trofinetide Japan trial results anticipated Sep–Nov 2026; Delphi panel recommends DAYBUE as Rett syndrome standard of care.","Reaffirms full-year 2026 financial guidance (no specific numbers provided)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":268062000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91084,"accession_number":"0001193125-26-197957","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Acadia R&D Head Elizabeth Thompson plans retirement; stays through 2026 as consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Thompson will retire for personal reasons; remains as Head of R&D until successor appointed, then consultant through end of 2026.","She will stay through readout of Phase 2 remlifanserin in Alzheimer's disease psychosis and into early Phase 3.","Company has initiated a search for a new Head of R&D; all ongoing clinical trials continue as planned.","Thompson joined Acadia in 2024 and helped strengthen clinical capabilities and advance pipeline programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100994,"accession_number":"0001193125-26-092213","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acadia Pharmaceuticals appoints Jonathan M. Poole to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Poole appointed effective March 3, 2026 as Class II director, term expiring at 2027 annual meeting.","He will serve on the Audit Committee; receives $50k annual cash retainer plus $12.5k for committee role.","Initial equity grant with $200k target fair value (split options/RSUs); prorated annual grant of $95,300.","Future annual equity grants of $400k (half options, half RSUs) with quarterly vesting over one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100993,"accession_number":"0001193125-26-071674","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q4 2025 GAAP revenue $284M; FY25 $1.07B; NUPLAZID $174M, DAYBUE $110M; FY26 guidance $1.22-1.28B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 GAAP total revenue $284M; non-GAAP adjusted $298M (+16% YoY); FY25 GAAP $1.07B, non-GAAP $1.08B.","GAAP NUPLAZID net sales $174M (includes $20M IRA rebate adjustment); non-GAAP adjusted $189M, up 17% vs Q4 2024.","DAYBUE net sales $110M in Q4 (+13% YoY) and $391M for FY25.","Net income Q4 $274M ($1.60 diluted EPS) including $250M tax benefit; FY net income $391M ($2.30 EPS). Cash & investments $820M.","FY 2026 guidance: total revenue $1.22-1.28B; NUPLAZID $760-790M; DAYBUE $460-490M; R&D $385-410M; SG&A $660-700M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1071505000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100992,"accession_number":"0001193125-26-011706","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acadia Pharmaceuticals reaffirms 2025 net sales guidance above $1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance.","Presented at J.P. Morgan Healthcare Conference on January 13, 2026.","Corporate slide presentation posted on ir.acadia.com for investor access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117321,"accession_number":"0001193125-25-266959","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q3 revenue $278.6M (+11% YoY); net income $71.8M; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product sales: NUPLAZID $177.5M (+12% YoY), DAYBUE $101.1M (+11% YoY).","Q3 net income $71.8M ($0.42 diluted EPS) vs. $32.8M ($0.20) in Q3 2024.","Full-year 2025 total revenue guidance raised to $1.07-1.095B from $1.045-1.095B.","NUPLAZID guidance raised to $685-695M; DAYBUE guidance tightened to $385-400M.","Cash & investments $847M at Sept 30, 2025 vs. $756M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":787516000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117320,"accession_number":"0001193125-25-262610","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Daniel B. Soland resigns from Acadia board and governance committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation effective October 30, 2025.","Mr. Soland stepped down from the Board and as Chair of Nominating and Corporate Governance Committee.","Resignation not due to any dispute or disagreement with the Company or Board.","No replacement for the Board seat or committee chair has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133757,"accession_number":"0000950170-25-104092","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q2 revenue $264.6M (+9% YoY); NUPLAZID guidance raised to $665-690M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $264.6M, NUPLAZID $168.5M (+7%), DAYBUE $96.1M (+14%).","Net income $26.7M ($0.16 EPS) vs $33.4M ($0.20 EPS) YoY due to higher tax rate.","Raised NUPLAZID net sales guidance low end to $665M; total revenue guidance $1.045-1.095B.","Patent litigation wins affirm NUPLAZID exclusivity through 2030 (composition) and 2038 (formulation).","COMPASS PWS Phase 3 study enrollment complete; top-line results expected early Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":508882000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150480,"accession_number":"0001193125-25-138452","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Federal Circuit affirms Acadia's NUPLAZID patent validity in MSN litigation","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. Court of Appeals affirmed District Court decision confirming validity of Acadia's '740 composition of matter patent for NUPLAZID (pimavanserin).","Ruling came in patent litigation against MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc.","Protects Acadia's intellectual property for NUPLAZID, used to treat Parkinson's disease psychosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150479,"accession_number":"0001193125-25-130620","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acadia shareholders elect three Class III directors, approve say-on-pay, ratify EY auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Catherine Owen Adams, Laura A. Brege, and Elizabeth A. Garofalo, M.D. as Class III directors; each received >129M votes for.","Advisory vote on named executive officer compensation approved: 142.2M for, 2.8M against, 108.8K abstain.","Ernst & Young LLP ratified as independent auditor for FY2025: 154.5M for, 926.5K against, 35.0K abstain.","Broker non-votes of 10.3M shares on director election and advisory compensation vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150478,"accession_number":"0001193125-25-123175","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Acadia wins patent litigation for NUPLAZID; court rules for Acadia on infringement and validity","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Delaware ruled in Acadia's favor in Pimavanserin II Cases regarding '721 formulation patent for NUPLAZID.","Court ruled for Acadia on both infringement and validity arguments against Aurobindo Pharma and MSN Laboratories.","Acadia entered a 12-year lease for ~52,771 sq ft Princeton executive office; 210 Lease starts by Jan 2026 with $1.9M first-year rent.","Amended current 502 Lease to terminate 5 days after 210 Lease commencement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150477,"accession_number":"0000950170-25-065672","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q1 revenue +19% to $244.3M; net income $19M; ACP-101 results accelerated to Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 revenue $244.3M, up 19% YoY; NUPLAZID sales $159.7M (+23%), DAYBUE $84.6M (+11%)","Net income $19.0M ($0.11/sh) vs $16.6M ($0.10/sh) in Q1 2024; cash $681.6M","DAYBUE record 954 unique patients shipped; 30% field force expansion completed; first EU patient served","COMPASS PWS Phase 3 topline results now expected early Q4 2025 (accelerated); if positive, NDA submission Q1 2026","2025 guidance reiterated: total rev $1.03-1.095B; R&D expense raised to $330-350M due to study acceleration"],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":244317000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150476,"accession_number":"0001193125-25-082809","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Acadia Pharmaceuticals amends bylaws, tightens stockholder nomination and meeting rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum threshold changed from majority of outstanding shares to majority of voting power.","Stockholder nominees limited to number of directors to be elected; substitute nominees prohibited.","Advance notice window widened: alternative window applies if annual meeting delayed >70 days (was 30).","Mandatory indemnification and expense advancement for directors/officers expanded to maximum extent allowed.","Exclusive forum provisions clarified, including U.S. federal district courts for Securities Act claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169449,"accession_number":"0000950170-25-027759","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q4 net income $143.7M; FY2024 revenue $957.8M (+32%); guides FY2025 rev $1.03-1.095B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total net product sales $957.8M, up 32% YoY; NUPLAZID $609.4M (+11%), DAYBUE $348.4M (+97%).","Q4 net income $143.7M ($0.86 EPS) vs $45.8M ($0.28 EPS) in Q4 2023; includes $146.5M PRV sale gain.","FY2024 net income $226.5M ($1.37 EPS) vs net loss of $61.3M ($0.37 loss per share) in FY2023.","FY2025 guidance: total revenue $1.03-1.095B; NUPLAZID $650-690M; DAYBUE $380-405M; R&D $310-330M; SG&A $535-565M.","Cash and investments $756.0M at Dec 31, 2024, up from $438.9M; EMA submission for trofinetide completed."],"consensus_eps_estimate":null,"consensus_eps_actual":1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":957797000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186501,"accession_number":"0001193125-24-275595","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Acadia sells Rare Pediatric Disease PRV for $150M, one third to partner Neuren","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of PRV for $150M on Dec 11, 2024, after HSR waiting period expired.","PRV awarded March 2023 from FDA approval of DAYBUE (trofinetide) for Rett syndrome.","One third of net proceeds payable to Neuren under July 2023 joint venture agreement.","Material terms of PRV Transfer Agreement previously disclosed in Q3 2024 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186500,"accession_number":"0001193125-24-262556","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acadia Pharma terminates COO Brendan Teehan without cause; CEO assumes duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan Teehan, EVP, COO and Head of Commercial, involuntarily terminated without Cause effective Nov 18, 2024.","Teehan will remain a non-executive employee until Dec 31, 2024 to assist transition.","CEO Catherine Owen Adams, with 30+ years pharma commercial experience, will assume his responsibilities until a successor is appointed.","No successor has been named; search for replacement is underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186499,"accession_number":"0000950170-24-122322","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q3 total revenue $250.4M (+18% YoY); net income $32.8M vs year-ago loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NUPLAZID sales $159.2M (+10% YoY); DAYBUE sales $91.2M (+36% YoY).","Net income $0.20 per share vs ($0.40) loss; nine-month net income $82.7M.","Full-year guidance: NUPLAZID $600-610M, DAYBUE $340-350M, total revenue $940-960M.","Entered agreement to sell Rare Pediatric Disease PRV for $150M; one-third of net to Neuren.","Health Canada approved DAYBUE for Rett syndrome under Priority Review."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":698195000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203079,"accession_number":"0001193125-24-223726","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Acadia CEO Stephen R. Davis terminated Sept 23; Catherine Owen Adams appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen R. Davis involuntarily terminated without cause as President and CEO effective Sept 23, 2024; resigns from board.","Davis receives severance: 1.5x base+target bonus, pro-rata 2024 bonus, 12 months accelerated equity, 18 months COBRA.","Catherine Owen Adams appointed CEO and director effective Sept 23; previously SVP and GM U.S. at BMS overseeing $20B business.","Adams compensation: $900k base salary, 80% target bonus, $500k sign-on, plus equity awards of $3.25M in options and $3.25M in PSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203078,"accession_number":"0000950170-24-091826","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q2 total revenue up 46% to $242M; net income $33.4M vs $1.1M last year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NUPLAZID net sales $157.4M (+11% YoY); DAYBUE net sales $84.6M (vs $23.2M YoY).","Net income $33.4M ($0.20 EPS) vs $1.1M ($0.01 EPS) in Q2 2023.","NUPLAZID FY guidance raised to $590-610M; DAYBUE lowered to $340-370M.","Total revenue FY guidance revised to $930-980M (from $930M-$1.01B).","Cash and investments $500.9M at June 30, 2024, up from $438.9M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":447794000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219369,"accession_number":"0001193125-24-149336","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Acadia shareholders elect directors, approve 2024 equity plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Julian C. Baker, Stephen R. Biggar, and Daniel B. Soland elected as Class II directors.","2024 Equity Incentive Plan approved with 131.3M votes for, 9.4M against.","Say-on-pay advisory vote passed with 132.99M for, 7.64M against.","Ernst & Young ratified as independent auditor for FY2024 with 150.0M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219368,"accession_number":"0000950170-24-055647","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q1 revenue $205.8M (+74% YoY), net income $16.6M vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NUPLAZID net sales $129.9M (+10% YoY); DAYBUE net sales $75.9M (vs $0 in Q1 2023)","Net income of $16.6M ($0.10 EPS) compared to net loss of $43.0M ($0.27 loss) in Q1 2023","Full-year 2024 guidance reiterated: DAYBUE $370-420M, NUPLAZID $560-590M","Cash and investments $470.5M at quarter end, up from $438.9M at Dec 31 2023","Appointed Elizabeth H.Z. Thompson as EVP, Head of R&D"],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":205831000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239199,"accession_number":"0001193125-24-064791","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ACAD's Phase 3 ADVANCE-2 trial of pimavanserin misses primary endpoint in negative symptoms of schizophrenia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pimavanserin failed Phase 3 ADVANCE-2 trial for negative symptoms of schizophrenia; primary endpoint not met.","Safety and tolerability consistent with prior trials, showing low adverse event rate.","No financial or regulatory guidance provided in this 8-K; further analysis may follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239198,"accession_number":"0000950170-24-021169","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Pharma Q4 net income $45.8M; 2023 revenue $726.4M (+40%); FY2024 DAYBUE guide $370-420M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net income $45.8M ($0.28 EPS) vs net loss $41.7M ($0.26 loss) in Q4 2022.","Full year 2023 net loss $61.3M ($0.37 loss) vs net loss $216.0M ($1.34 loss) in 2022.","2023 total net product sales $726.4M (+40% YoY); DAYBUE $177.2M, NUPLAZID $549.2M (+6%).","FY2024 guidance: DAYBUE net sales $370-420M; NUPLAZID $560-590M; R&D $305-325M; SG&A $455-480M.","Phase 3 ADVANCE-2 (pimavanserin for negative schizophrenia) top-line results due by end of Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":726437000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239197,"accession_number":"0001193125-24-019903","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acadia EVP, General Counsel Austin Kim departs; transition period","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Austin D. Kim, Executive VP, General Counsel & Secretary, leaves Acadia to pursue other opportunities.","Mr. Kim will remain a non-executive employee during a transition period to assist with orderly handover.","No successor has been named as of the announcement date (January 30, 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256706,"accession_number":"0001193125-23-281574","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Acadia Pharma EVP R&D Doug Williamson to depart; search for replacement underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Doug Williamson, MD, EVP Head of R&D, leaving Acadia to pursue other opportunities.","Williamson joined Acadia in January 2023 and will remain during a transitional period.","Company has initiated a search for a replacement EVP of Research and Development.","No financial impact or guidance changes disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256705,"accession_number":"0000950170-23-058254","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q3 2023 record revenue $211.7M; DAYBUE launch strong at $66.9M, NUPLAZID grows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $211.7M; DAYBUE net sales $66.9M (first full quarter), NUPLAZID $144.8M, up from $130.7M YoY","Net loss $65.2M ($0.40 per share) vs $27.2M loss YoY; includes $100M upfront for worldwide DAYBUE rights","Full-year 2023 guidance: NUPLAZID net sales $537.5-545M; R&D $340-350M; SG&A $390-400M","Plans to start Phase 3 for ACP-101 (Prader-Willi) and Phase 2/3 for ACP-204 (Alzheimer's psychosis) in Q4 2023","Appoints Albert Kildani as SVP IR and Stephanie Kim as SVP Regulatory Affairs"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":211699000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274076,"accession_number":"0000950170-23-037216","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q2 net income $1.1M; DAYBUE launch strong with $23.2M sales; guides Q3 DAYBUE $45-55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net income of $1.1M ($0.01/share) vs net loss of $34.0M in prior year; total product sales $165.2M.","DAYBUE (trofinetide) first full quarter of sales: $23.2M; expanded licensing deal with Neuren for global rights.","NUPLAZID Q2 sales $142.0M, +5.5% YoY; full year guidance raised to $530-545M.","R&D expenses decreased to $58.8M; SG&A increased to $96.0M due to DAYBUE launch costs.","Appointed Dr. Kevin R. Oliver as SVP, Chief Business Officer; Phase 3 negative symptoms schizophrenia trial enrollment complete, results Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":165235000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274075,"accession_number":"0001193125-23-188839","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Acadia expands trofinetide rights globally; Q2 DAYBUE net sales $21-23M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acadia pays Neuren $100M upfront for ex-North American trofinetide rights and global NNZ-2591 rights in Rett/Fragile X.","Potential milestone payments up to $405M each for trofinetide and NNZ-2591 in North America; additional milestones outside NA.","Preliminary Q2 2023 DAYBUE net sales $21-23M; Q3 guidance $45-55M.","NUPLAZID Q2 preliminary net sales $140-144M; full year 2023 guidance $530-545M.","Acadia to submit NDS for trofinetide in Canada within 18 months; plans for Europe, Asia later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291245,"accession_number":"0001193125-23-159833","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acadia shareholders elect three Class I directors, approve say-on-pay, and ratify EY as auditor on annual basis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected James M. Daly, Edmund P. Harrigan, and Adora Ndu as Class I directors (for votes: 108.2M, 126.2M, 131.6M).","Advisory say-on-pay approved with 87.3M for vs. 48.3M against; broker non-votes 9.9M.","Stockholders favored annual advisory vote on executive compensation (135.1M votes for 1 year); board adopts annual frequency.","Ratification of Ernst & Young as independent auditor for FY2023 approved (144.9M for, 0.5M against, 0.1M abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291244,"accession_number":"0000950170-23-018800","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q1 net loss narrows to $43M; DAYBUE approved and launched for Rett syndrome","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NUPLAZID net sales $118.5M, up 3% YoY; demand grew ~2%.","Net loss $43.0M ($0.27/share) vs $113.1M ($0.70/share) in Q1 2022.","DAYBUE (trofinetide) FDA-approved March 10; launched April 17 for Rett syndrome.","Phase 3 pimavanserin trial for negative schizophrenia symptoms nearing enrollment; results expected early 2024.","2023 guidance reaffirmed: NUPLAZID sales $520-$550M, R&D $235-$255M, SG&A $360-$380M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":118462000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312033,"accession_number":"0001193125-23-068406","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Acadia discloses $9.2M total exposure to failed Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately $1M in deposit accounts at SVB for daily cash needs as of March 10, 2023.","Approximately $5.8M in restricted cash in money-market accounts as collateral for office leases and corporate charge card.","Approximately $2.4M in receivables in a lockbox account at SVB.","Company states exposure to SVB is limited; total disclosed exposure about $9.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312032,"accession_number":"0000950170-23-004753","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Pharma Q4 NUPLAZID sales $136.5M, full-year $517.2M; PDUFA for trofinetide March 12","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $517.2M in 2022, up 7% YoY; Q4 sales $136.5M, up 4% YoY.","Net loss $216.0M for 2022 vs $167.9M in 2021; Q4 loss $41.7M ($0.26/share).","PDUFA action date March 12, 2023 for trofinetide for Rett syndrome.","2023 guidance: NUPLAZID sales $520-550M; R&D $235-255M; SG&A $360-380M.","Doug Williamson appointed EVP Head of R&D in Jan 2023; Serge Stankovic retired."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":517235000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330620,"accession_number":"0000950170-22-021222","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q3 net sales $130.7M (-1% YoY), net loss widens; trofinetide PDUFA Mar 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $130.7M (-1% YoY); net loss $27.2M ($0.17 loss/share) vs $14.5M loss a year ago.","FY 2022 NUPLAZID guidance narrowed to $510-520M from $510-540M; R&D and SG&A guides trimmed.","FDA accepted trofinetide NDA for Rett syndrome with priority review; PDUFA action date March 12, 2023.","President Serge Stankovic to retire at year-end; search ongoing. Adora Ndu appointed to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":130714000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330619,"accession_number":"0001193125-22-272491","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"President Srdjan R. Stankovic to retire Dec 31, 2022; will remain as consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Srdjan R. Stankovic notified Acadia of his retirement as President, effective Dec 31, 2022.","He will continue in his current role through Dec 31 and then serve as consultant and advisor.","No replacement President has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330618,"accession_number":"0001193125-22-262140","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2022-10-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acadia appoints Adora Ndu to board, increases size to nine directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 8 to 9 members; Adora Ndu, Pharm.D., J.D. appointed effective Oct 12, 2022.","Dr. Ndu serves as Class I director with term expiring at 2023 Annual Meeting.","Receives standard director compensation: stock option and RSU award each with $150,000 fair value.","Will not initially serve on any board committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348126,"accession_number":"0000950170-22-015527","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q2 NUPLAZID sales $134.6M (+17% YoY); NDA filed for trofinetide in Rett syndrome","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $34.0M ($0.21/share) vs $43.9M loss in Q2 2021; six-month loss $147.1M.","R&D expense $75.6M vs $56.9M YoY; SG&A $89.9M vs $96.8M on lower promo costs.","NDA submitted to FDA for trofinetide for Rett syndrome; CRL received for pimavanserin in Alzheimer's psychosis.","Discontinued development of ACP-044 (pain) and ACP-319 (M1 PAM) based on data review.","2022 NUPLAZID revenue guidance narrowed to $510-540M from $510-560M; R&D guidance reduced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":134563000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364777,"accession_number":"0001193125-22-171917","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Acadia stockholders approve 6M share increase for equity plan, elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2010 Equity Incentive Plan, increasing authorized shares by 6,000,000 (135.2M for, 6.6M against).","Class III directors Laura A. Brege, Stephen R. Davis, and Elizabeth A. Garofalo elected with 89.4M, 127.1M, and 117.4M votes for, respectively.","Advisory vote on executive compensation approved (127.2M for, 3.4M against).","Ratification of Ernst & Young as independent auditor for FY2022 passed (141.5M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364776,"accession_number":"0000950170-22-007402","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q1 NUPLAZID sales $115.5M (+8% YoY); net loss widens to $113.1M on $60M Stoke payment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 NUPLAZID net sales $115.5M (+8% vs $106.6M Q1 2021); net loss $113.1M ($0.70/sh) vs $66.4M loss in prior year.","R&D expense surged to $128.9M from $57.0M, driven by $60M upfront payment to Stoke Therapeutics under license deal.","Cash and investments $446.0M at March 31, 2022, down from $520.7M at Dec 31, 2021.","FY2022 NUPLAZID net sales guidance reiterated at $510-$560M; FDA AdComm for pimavanserin in ADP set for June 17, 2022.","Trofinetide NDA for Rett syndrome on track for mid-2022; Parag Meswani and Holly Valdiviez joined as senior commercial leads."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":115468000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364775,"accession_number":"0001193125-22-100541","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acadia grants retention RSUs to CEO, President, and General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Stephen R. Davis receives 277,331 RSUs; President Srdjan R. Stankovic 144,695 RSUs; EVP Gen. Counsel Austin D. Kim 96,463 RSUs.","RSUs vest: 37.5% at 18 months, 12.5% at 2 years, 25% at 3 years, 25% at 4 years from grant date.","Awards granted under Acadia's 2010 Equity Incentive Plan, with accelerated vesting in certain circumstances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384404,"accession_number":"0000950170-22-002291","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia reports $484.1M 2021 net sales (+10% YoY); net loss narrows to $167.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net product sales $130.8M (+8% YoY); full-year net sales $484.1M (+10% YoY).","Q4 net loss $43.1M ($0.27/sh) vs. $66.8M ($0.42/sh) in Q4 2020; full-year loss $167.9M ($1.05/sh).","Resubmitted sNDA for pimavanserin in Alzheimer's disease psychosis; Phase 3 Lavender trial of trofinetide in Rett syndrome positive.","FY2022 guidance: NUPLAZID net sales $510-560M; R&D expense $355-375M; SG&A $360-380M.","Cash and investments $520.7M at Dec 31, 2021, down from $632.0M a year earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":484145000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402238,"accession_number":"0001193125-21-362806","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Acadia plans Q1 2022 sNDA resubmission for pimavanserin in Alzheimer's disease psychosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmission targets Alzheimer's disease psychosis (ADP) instead of broader dementia-related psychosis.","sNDA includes data from two positive Phase 3 studies: HARMONY and -019, meeting primary endpoints.","New analyses address FDA complete response letter concerns; plan follows three meetings with FDA.","CEO Steve Davis says narrowed indication and additional data support case for first ADP drug approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402237,"accession_number":"0001193125-21-356869","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2021-12-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Acadia names Mark Schneyer permanent CFO; previously interim CFO since Sept 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Schneyer appointed EVP, CFO effective Dec 9, 2021; had served as interim CFO since Sept 2021.","Schneyer previously SVP, Business Development and CBO; joined Acadia from Pfizer in May 2020.","He led the Dec 2020 acquisition of CerSci Therapeutics, adding a Phase 2-ready pain program.","Schneyer retains responsibility for business development and investor relations; reports to CEO Steve Davis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402236,"accession_number":"0001193125-21-349137","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2021-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Acadia reports positive Phase 3 trofinetide results in Rett syndrome; NDA plan mid-2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trofinetide met co-primary endpoints: RSBQ change -5.1 vs -1.7 (p=0.0175); CGI-I 3.5 vs 3.8 (p=0.003).","Key secondary endpoint CSBS-DP-IT-Social also met: -0.1 vs -1.1 (p=0.0064); effect size 0.43.","Discontinuation due to AEs 17.2% trofinetide vs 2.1% placebo; diarrhea (80.6%) and vomiting (26.9%) most common.","Pre-NDA meeting with FDA planned Q1 2022; NDA submission expected mid-2022; Fast Track, Orphan, RPD designations granted.","More than 95% of completers rolled into open-label Lilac extension; Acadia licensed trofinetide from Neuren Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402235,"accession_number":"0001564590-21-055255","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Pharma Q3 net loss narrows to $0.09/shr; NUPLAZID sales up 9% to $131.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share of $0.09, improved from $0.54 loss in Q3 2020; revenue $131.6M (+9% YoY).","2021 NUPLAZID sales guidance narrowed to $480M-$500M from $480M-$515M; R&D guidance lowered.","FDA meeting scheduled to discuss pimavanserin sNDA resubmission for dementia-related psychosis subgroups.","Top-line results expected Q4 2021 for trofinetide (Rett syndrome) and Q1 2022 for ACP-044 (pain).","Promoted Brendan Teehan to EVP, COO, Head of Commercial; Julie Fisher to SVP, Marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":131612000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402234,"accession_number":"0001193125-21-321667","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2021-11-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Acadia appoints Brendan Teehan as EVP, COO, Head of Commercial; two executives depart","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan Teehan promoted to EVP, Chief Operating Officer and Head of Commercial, effective immediately.","Teehan previously SVP, Chief Insights and Analytics Officer; will lead all sales and marketing functions.","Charmaine Lykins (SVP, Global Product Planning) and Amanda Morgan (SVP, Chief Revenue) leaving after transition period.","Teehan has over 25 years healthcare experience, previously at Johnson & Johnson, Amgen, TESARO.","Appointment comes as Acadia prepares for next phase of growth, per CEO Steve Davis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421186,"accession_number":"0001193125-21-264582","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2021-09-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acadia CFO Elena Ridloff resigns; CEO Davis named principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elena Ridloff resigned as EVP and CFO effective September 10, 2021.","CEO Stephen Davis appointed as principal financial officer.","Mark Schneyer appointed interim CFO; remains SVP and Chief Business Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421185,"accession_number":"0001564590-21-040825","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia cuts FY2021 NUPLAZID revenue guidance to $480-515M; FDA reiterates need for additional DRP studies","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2Q21 net sales $115.2M (+5% YoY); net loss $43.9M ($0.27/share) vs $42.1M loss in 2Q20.","FY2021 revenue guidance reduced to $480-515M from $510-550M due to pandemic and higher gross-to-net (~20%).","FDA Type A meeting on pimavanserin for DRP: FDA insists on additional studies per subgroup but open to further discussion.","GAAP R&D guidance lowered to $250-270M (prior $280-300M); SG&A guidance unchanged at $385-415M.","Phase 3 LAVENDER (trofinetide for Rett syndrome) top-line expected Q4 2021; Phase 2 ACP-044 pain results also Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":115221000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}